AstraZeneca's deal with Vanguard Renewables will use the biogas produced from food waste and manure at farms like this one in Vermont. (AstraZeneca)

June 13, 2023 02:49 PM EDT

Pharma

Marketing

AstraZeneca amps environmental goals with deal for renewable fuel use at all US sites

Beth Snyder Bulik

Senior Editor

AstraZeneca is pushing its greenhouse gas emissions goals forward, teaming up with a provider of renewable natural gas created from animal and food waste for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca amps environmental goals with deal for renewable fuel use at all US sites

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

GSK leaves biotech trade group BIO

Biotech industry worries over potential for RFK Jr. ally as FDA pick

BenevolentAI’s co-founder is back. Here’s how he plans a turnaround at the AI company during a ‘pivotal time’

Legend names a president of Carvykti; Novo Nordisk's top North America exec is stepping down

Eisai slashes Leqembi sales forecast by almost $100M

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

As­traZeneca amps en­vi­ron­men­tal goals with deal for re­new­able fu­el use at all US sites

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

GSK leaves biotech trade group BIO

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Benev­o­len­tAI’s co-founder is back. Here’s how he plans a turn­around at the AI com­pa­ny dur­ing a ‘piv­otal time’

Leg­end names a pres­i­dent of Carvyk­ti; No­vo Nordisk's top North Amer­i­ca ex­ec is step­ping down

Ei­sai slash­es Leqem­bi sales fore­cast by al­most $100M

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

AstraZeneca amps environmental goals with deal for renewable fuel use at all US sites

Biotech industry worries over potential for RFK Jr. ally as FDA pick

BenevolentAI’s co-founder is back. Here’s how he plans a turnaround at the AI company during a ‘pivotal time’

Legend names a president of Carvykti; Novo Nordisk's top North America exec is stepping down

Eisai slashes Leqembi sales forecast by almost $100M

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks